<unk>  is a kinase inhibitor that is FDA approved for the treatment of patients, in combination with binimetinib, with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.   Common adverse reactions include fatigue, nausea, vomiting, abdominal pain, and arthralgia.
Encorafenib
Regorafenib
Afatinib
Neratinib
Brigatinib
Dasatinib
Fostamatinib
Erdafitinib